Swedish Orphan Biovitrum
324.20 SEK
-0.61 %
Less than 1K followers
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.61 %
-3.74 %
+17.63 %
+15.13 %
+2.14 %
+4.38 %
+54.49 %
+102.21 %
+579.40 %
Swedish Orphan Biovitrum operates in the pharmaceutical industry and focuses on the development and distribution of medicines for rare diseases. The company's products are aimed at healthcare institutions and patients with specific medical needs. The business is global with a main presence in Europe, North America and Asia. Swedish Orphan Biovitrum was founded in 1939 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
115.87B SEK
Turnover
124.97M SEK
Revenue
26.03B
EBIT %
21.61 %
P/E
28.51
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5/2
2026
Annual report '25
28/4
2026
Interim report Q1'26
6/5
2026
General meeting '26
All
Press releases
ShowingAll content types
Swedish Orphan Biovitrum AB: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Swedish Orphan Biovitrum AB: Förändring i Sobis styrelse
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools